Heatwurx Inc. (NASDAQ:PCSA) Short Interest Update

Heatwurx Inc. (NASDAQ:PCSA) was the recipient of a large drop in short interest during the month of December. As of December 31st, there was short interest totaling 98,000 shares, a drop of 97.2% from the December 15th total of 3,454,719 shares. Currently, 4.4% of the shares of the stock are sold short. Based on an average daily volume of 4,086,107 shares, the short-interest ratio is currently 0.0 days. Based on an average daily volume of 4,086,107 shares, the short-interest ratio is currently 0.0 days. Currently, 4.4% of the shares of the stock are sold short.

Heatwurx Stock Up 0.6%

PCSA stock traded up $0.02 during trading on Tuesday, hitting $3.16. The company had a trading volume of 25,727 shares, compared to its average volume of 100,343. The firm has a 50-day moving average price of $5.62 and a 200-day moving average price of $5.92. Heatwurx has a 12 month low of $2.74 and a 12 month high of $22.80. The stock has a market cap of $7.17 million, a price-to-earnings ratio of -0.09 and a beta of 1.13.

Heatwurx (NASDAQ:PCSA) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($1.75) EPS for the quarter, beating analysts’ consensus estimates of ($2.00) by $0.25. Equities analysts expect that Heatwurx will post -4.05 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on PCSA shares. Wall Street Zen raised shares of Heatwurx from a “sell” rating to a “hold” rating in a report on Saturday, January 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heatwurx in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $25.00.

About Heatwurx

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.